Cefprozil

證據等級: L5

預測適應症: 10 個

Cefprozil: From Respiratory Tract Infections to Urinary Tract Infection

One-Sentence Summary

Cefprozil is an oral second-generation cephalosporin antibiotic, originally developed for upper and lower respiratory tract infections and skin/soft tissue infections. The TxGNN model predicts it may be effective for Urinary Tract Infection, with no registered clinical trials but 9 publications—including 3 comparative RCTs—currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Respiratory tract infections, skin and soft tissue infections
Predicted New Indication	Urinary Tract Infection
TxGNN Prediction Score	99.99%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from DrugBank for this drug record. Based on known pharmacological information from the published literature, Cefprozil is an oral second-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This disrupts peptidoglycan cross-linking and leads to cell lysis. The Evidence Pack's repurposing rationale specifically confirms that cefprozil demonstrates well-characterised PBP inhibitory activity against the major uropathogens responsible for uncomplicated UTI — Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus.

The connection between respiratory infections and urinary tract infections is mechanistic rather than anatomical. Both settings involve common community-acquired pathogens susceptible to beta-lactam antibiotics. Cefprozil's broad-spectrum profile — notably active against both gram-positive cocci and gram-negative Enterobacteriaceae — means the same mechanism of action that clears respiratory pathogens also targets the bacteria most responsible for uncomplicated UTIs. Its oral bioavailability and documented urinary excretion further support adequate drug concentrations at the infection site.

This prediction is therefore not a speculative leap. Three independent randomised trials conducted in the early 1990s already demonstrated that cefprozil achieves clinical and bacteriological cure rates comparable to cefaclor in adults and children with acute uncomplicated UTI. The TxGNN model is largely confirming an evidence-backed application that has not yet been formally registered as an approved indication in Taiwan.

Clinical Trial Evidence

Currently no related clinical trials registered for Cefprozil in urinary tract infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1761453	1991	Comparative RCT	J Antimicrobial Chemother	Cefprozil 500 mg once daily vs cefaclor 250 mg TID in 102 adults with acute uncomplicated UTI; efficacy comparable, supporting simplified once-daily dosing
1952874	1991	Comparative RCT	Antimicrob Agents Chemother	108 college women with acute UTI: cefprozil once daily vs cefaclor TID for 10 days; clinical cure ~94% and bacterial cure ~93% for cefprozil, not significantly different from cefaclor
1611652	1992	Comparative RCT	Clinical Therapeutics	Multicenter RCT (patients ≥2 years) comparing cefprozil once daily vs cefaclor TID for 10 days in acute uncomplicated UTI; satisfactory clinical response rates comparable between groups
1494237	1992	Prospective Clinical Study	Jpn J Antibiotics	Pediatric PK study of cefprozil granules; serum and urinary concentrations confirmed; 3 UTI cases included with good clinical outcomes
1289583	1992	Prospective Clinical Study	Jpn J Antibiotics	21 children with acute bacterial infections including 3 UTI cases; good-to-excellent clinical response in 19/21 patients; complete bacterial eradication achieved in all 11 culture-confirmed cases
8529432	1995	In Vitro Study	Chemotherapy	Taiwan-based in vitro study of 637 clinical isolates: cefprozil inhibited >80% of E. coli and K. pneumoniae at 8 mg/L, confirming activity against key UTI uropathogens in a local clinical context
7681376	1993	Review	Drugs	Comprehensive review of cefprozil's antibacterial spectrum, pharmacokinetics, and therapeutic applications; documents activity against Enterobacteriaceae and urinary pathogens
8464648	1993	Review	Pediatric Annals	Overview of cefprozil in pediatric infections; notes potential role in management of respiratory, skin, and urinary tract infections given its safety profile and dosing convenience
8042575	1994	Review	Am Family Physician	Comparative review of newer oral cephalosporins; concludes cefprozil is effective for skin, respiratory, and urinary tract infections, highlighting twice-daily dosing as a clinical advantage

Taiwan Market Information

Cefprozil is currently not marketed in Taiwan. No drug license applications or approved authorizations are on record. Patients in Taiwan requiring cefprozil would not currently have access to a domestically approved product.

Safety Considerations

Please refer to the package insert for safety information.

No safety data (warnings, contraindications, or drug-drug interactions) was retrievable from the current data sources. The package insert from TFDA or FDA should be reviewed before any clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three independent comparative RCTs consistently demonstrated that cefprozil 500 mg once daily is as safe and effective as cefaclor for acute uncomplicated UTI, with clinical cure rates of approximately 93–94%. The mechanistic rationale — PBP inhibition of common uropathogens with confirmed urinary excretion — is directly applicable, and the TxGNN prediction score of 99.99% is well-supported by the existing literature body.

To proceed, the following is needed:

Safety profile completion: Obtain TFDA/FDA package insert warnings, contraindications, and precautions (currently blocking the formal safety screen)
MOA documentation: Retrieve full mechanism of action data from DrugBank to complete the mechanistic dossier
DDI screening: Conduct drug-drug interaction review for common co-medications in UTI patient populations
Resistance landscape assessment: Evaluate current antimicrobial susceptibility data for E. coli and Klebsiella in Taiwan — the existing RCTs are from 1991–1995, and local resistance patterns may have shifted significantly
Regulatory pathway review: Determine the regulatory requirements and feasibility for seeking Taiwan market authorization for the UTI indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.